{"id":84936,"date":"2021-09-20T07:17:43","date_gmt":"2021-09-20T11:17:43","guid":{"rendered":"http:\/\/stateofthenation.co\/?p=84936"},"modified":"2021-09-20T07:17:43","modified_gmt":"2021-09-20T11:17:43","slug":"risk-of-myocarditis-greater-than-covid-19-for-men-under-40","status":"publish","type":"post","link":"https:\/\/stateofthenation.co\/?p=84936","title":{"rendered":"Risk of Myocarditis Greater than COVID-19 for Men Under 40"},"content":{"rendered":"

FDA Committee Discussion Opines Men Under 40 at Greater Risk of Vaccine-Related Myocarditis than COVID Itself.<\/strong><\/h1>\n

ZeroHedge.com<\/p>\n

\n

Following the release of the Biden administration’s six-step plan to increase vaccination rates across the country, it seemed that their charge toward a de facto national vaccine mandate had reached terminal velocity. Yet, in advance of the administration’s decision to green light booster shots to address the waning efficacy of vaccines, their steadfast effort reached unexpected resistance from an even more unexpected source. On September 18, the FDA declared that its authorization for the expansion of booster shots beyond the immunocompromised would only apply to persons 65 years or older. The FDA committee which authorized the administration of boosters<\/a> for that 65+ demographic by a 18-0 vote issued an equally resounding vote against approving the measure for people below 65 by a vote of 16-3.<\/p>\n

At best, the decision was made at a time where data on the efficacy of boosters does not clearly support policy making expanding their authorization. When pressed on that very issue, CDC Director Rochelle Wallensky didn’t offer a resounding endorsement<\/a>\u00a0when she stated that “so there’s actually hope, we don’t have data yet.” Another less than stellar endorsement of expanding boosters came from a\u00a0study<\/a> published in the New England Journal of Medicine which examined the efficacy of the Israeli government’s booster initiative which began on July 30. While the study determined that the rate of infection was lower among recipients of booster shots, the threshold for the enhanced protection they achieved was only measured\u00a0at\u00a0a period of 12 days following the third dosage. Even then, the rate of infection only fell by around 11%. While these instances highlight the uncertainty of the long-term success of the Biden administrations booster initiative, the FDA panel discussion on the issue did highlight one thing with much greater certainty —\u00a0the risks of vaccination side effects can outweigh the risk of COVID-19 themselves.<\/p>\n

In a stark admission which has been drowned out by attempts to make the panels decision reflect well upon the Biden administration, an FDA Center for Biologics Evaluation and Research advisory panel\u00a0discussion declared that the risk of myocarditis being higher than COVID-19 in males under the age of 40.\u00a0The assertion was predicated upon public health claims data cited by Dr. Doran Fink of the FDA, who implored Pfizer to take a greater initiative to examine this very issue.\u00a0Given this profound point of demarcation, this topic of discussion during the FDA advisory panel’s meeting offers greater insight into the limited scope of the authorization of booster shots.<\/p>\n